SERA PROGNOSTICS TO PRESENT AT UPCOMING MARCH INVESTOR CONFERENCES
Sera Prognostics, known as The Pregnancy Company (NASDAQ: SERA), announced its participation in two significant upcoming healthcare conferences: the Cowen Health Care Conference in Boston from March 6-8, 2023, and the Oppenheimer 33rd Annual Healthcare Conference virtually from March 13-15, 2023. CEO Gregory C. Critchfield will provide updates on the company's progress, including its innovative PreTRM® Test, which aids in predicting preterm birth risk. Both conferences will feature live webcasts available on the company's investor page, ensuring accessible information for stakeholders.
- None.
- None.
Sera's management is scheduled to participate in a fireside chat on
Oppenheimer 33rd Annual Healthcare Conference
Sera's management will present on
These events will be webcast live on the Investors page of the Company's website at www.seraprognostics.com with archived webcasts available for 90 days afterward.
About
About Preterm Birth
Preterm birth is defined as any birth before 37 weeks' gestation and is the leading cause of illness and death in newborns. The 2022 March of Dimes Report Card shows that, for the last four consecutive years, more than one in ten infants is born prematurely. Prematurity is associated with a significantly increased risk of major long-term medical complications, including learning disabilities, cerebral palsy, chronic respiratory illness, intellectual disability, seizures, and vision and hearing loss, and can generate significant costs throughout the lives of affected children. The annual health care costs to manage short- and long-term complications of prematurity in the United States were estimated to be approximately
About the PreTRM® Test
The PreTRM® Test is the only broadly validated, commercially available blood-based biomarker test that provides an early, accurate and individualized risk prediction for spontaneous preterm birth in asymptomatic singleton pregnancies. The PreTRM® Test measures and analyzes proteins in the blood that are highly predictive of preterm birth. The PreTRM® Test permits physicians to identify, during the weeks 18 through 20 of pregnancy, which women are at increased risk for preterm birth and its complications, enabling more informed, personalized clinical decisions based on each woman's individual risk. The PreTRM® Test is ordered by a medical professional.
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the Company's planned presentations and one-on-one meetings with investors at the aforementioned investor conferences; and the company's strategic directives under the caption "About
View original content to download multimedia:https://www.prnewswire.com/news-releases/sera-prognostics-to-present-at-upcoming-march-investor-conferences-301754963.html
SOURCE
FAQ
What events is Sera Prognostics participating in March 2023?
Who will represent Sera Prognostics at the conferences?
When is the Cowen Health Care Conference presentation?
What is the focus of Sera Prognostics?
What is the PreTRM® Test by Sera Prognostics?